Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
Questions
About
The Positive and Negative Syndrome Scale (PANSS) was published in 1987 by Stanley Kay, Lewis Opler, and Abraham Fiszbein. It’s a scale used for measuring symptom severity of schizophrenia, and widely used in the study of psychopharmacologic therapy. The scale was based off the Psychopathology Rating Schedule (PRS) and the Brief Psychiatric Rating Scale (BPRS). The PANSS is a 30-item clinician-administered rating scale, but requires 45 to 50 minutes to be administered by a subject matter expert. The interviewer must be trained to a standardized level of reliability. The PANSS has been published officially across 40 languages and is used internationally in mostly clinical research.
The scale has mostly been used to inventory, grade and follow the symptoms in schizophrenia. It quantifies positive symptoms, which refer to an excess or distortion of normal functions (e.g., hallucinations and delusions), and negative symptoms, which represent a diminution or loss of normal functions. The PANSS is composed of 3 subscales: Positive Scale, Negative Scale, and General Psychopathology Scale. Each subscale is rated with 1 to 7 points ranging from absent to extreme. The range for the Positive and Negative Scales is 7-49, and the range for the General Psychopathology Scale is 16-112. The total PANSS score is simply the sum of the sub scales. In addition to these measures, a Composite Scale is scored by subtracting
the negative score from the positive score. This yields a bipolar index that ranges from –42 to +42, which is essentially a difference score reflecting the
degree of predominance of one syndrome in relation to the other.
The PANSS has been studied for its psychometric properties, and the data shows adequate Internal consistency, good test-retest reliability, and inter-rater reliability. In addition the PANSS has been researched in quality of life studies, functional status, natural history of schizophrenia and treatment outcomes. It has most of its evidence base to support its use for grading the severity of schizophrenia symptoms, staging of schizophrenia and treatment progress with medications. There is limited research that explains the degree of improvement in the total or subscale PANSS scores and how it is clinically important, or which break points for scores are best used for grading the severity of schizophrenia.
References
Kay SR.
Kay SR, Opler LA, Lindenmayer JP.
Kay SR, Opler LA, Lindenmayer JP.
Kay SR, Fiszbein A, Opler LA.
Peralta V, Cuesta MJ.
Fountoulakis KN, Dragioti E, Theofilidis AT, et al.
By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.